Cancer drug trial shows 100% success – Study

NEWS DIGEST – The United States (US) drug trial Involving cancer patients has recorded 100 per cent success among rectal cancer patients.

Rectal cancer is a type of cancer that begins in the rectum, which is the lower end of the large intestine.

According to a study published in the New England Journal of Medicine, the trial consisted of 12 patients, all of whom entered remission after taking dostarlimab cancer drug for six months.

Dostarlimab is an immunotherapy drug used in the treatment of endometrial cancer. It works by unmasking cancer cells, allowing the immune system to identify and destroy them.

The lead author of the paper, Luis Diaz, said he didn’t know of any other study in which a treatment completely got rid of cancer in every patient, “this is the first time this has happened in the history of cancer”.

He said a total of 12 patients completed treatment with dostarlimab cancer drug and also undergone at least 6 months of follow-up showing no evidence of tumour on magnetic resonance imaging, and endoscopic evaluation.

“At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up and no adverse events of grade 3 or higher have been reported.”

The scientists, however, noted that “longer follow-up is needed to assess the duration of response” and therefore cautioned against concluding that cancer had been eradicated permanently.